Influvac Tetra

B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202, the active ingredient in Influvac Tetra, is an inactivated influenza virus vaccine presented as an injectable solution for intramuscular or subcutaneous use. It is intended to prevent influenza infection in individuals at risk, including adults and children.

GNH USA supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for import and distribution, ensuring reliable supply chains across regions.

Influvac Tetra is an inactivated influenza vaccine used to prevent seasonal influenza infection.

Seasonal influenza: provides immunity against the influenza A(H1N1), A(H3N2), B/Victoria and B/Yamagata lineages included in the vaccine. High‑risk populations: reduces the likelihood of influenza‑related complications in elderly, immunocompromised or chronic‑disease patients. Pediatric use: offers protection for children aged 6 months and older as part of routine immunisation programmes.

Influvac Tetra, like other injectable vaccines, may be associated with local and systemic reactions.

Common Side Effects: - Pain, redness or swelling at the injection site. - Low‑grade fever (up to 38°C). - Headache or mild fatigue. - Myalgia (muscle aches).

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction. - Guillain‑Barré syndrome. - Seizures or high fever (>40°C). - Prolonged bleeding at the injection site. - Severe systemic reactions requiring medical attention.

Before administering Influvac Tetra, consider the following precautions.

Screen for severe allergy: verify no known hypersensitivity to any vaccine component. Delay vaccination: postpone in individuals with acute moderate or severe illness. Observe after injection: monitor for at least 15 minutes for immediate reactions. Avoid in known anaphylaxis: do not administer to persons with prior severe allergic reaction to influenza vaccines. Pregnancy and lactation: assess risk‑benefit; limited data available. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influvac Tetra may interact with other medicines or vaccines.

Major Interactions (Avoid): - Live vaccines: avoid co‑administration with live attenuated vaccines within 4 weeks. - Immunoglobulins: do not give within 3 months as they may reduce vaccine efficacy. - Antiviral drugs: concurrent use of neuraminidase inhibitors may interfere with immune response.

Moderate Interactions (Monitor Closely): - Immunosuppressive therapy: monitor antibody response, may need revaccination. - Febrile illness: may increase risk of systemic reactions; consider timing. - Allergic medications: antihistamines may mask early allergic signs; observe closely.